Top Tweets for #endocrinetherapy
GPER is emerging as an important player in endocrine therapy resistance in breast cancer. Discover new therapeutic opportunities for overcoming resistance and improving treatment response.
https://t.co/3Sokt3FAm8
#BreastCancer #EndocrineTherapy #GPER #TherapeuticResistance #TargetedTherapy
We are seeking participants for the #ATTITUDEstudy, a research study focused on understanding attitudes toward #EndocrineTherapy for #BreastCancer.
This study aims to validate a new measure of patients’ attitudes toward endocrine therapy and better understand their experiences with long-term treatment. The goal is to help identify patients who may struggle with #HormoneTherapy adherence and improve support strategies that help patients stay on treatment and reduce the risk of recurrence.
For more information email: [email protected]
PI: @MeganTesch #ClinicalTrial #BreastCancerResearch
To investigate the role of slow growing cells in ER+ #BreastCancer recurrence, Dr. C. Elizabeth Caldon
and collaborators isolate and characterize slowly growing #EndocrineTherapy treated cells compared to their rapidly growing counterparts. 🧫 https://t.co/BT8d7xFrpc
Congratulations to the @GarvanInstitute team!
📚 Read their findings in @NatureComms. #OpenAccess
The #BreastCancer in Young Women session at #ESMObreast26 is one you don't want to miss!
Tune in tomorrow to hear #AYA expert, Dr. Ann Partridge (@AnnPartridgeMD), discuss the challenges of optimizing #EndocrineTherapy for young women.
🗓️ Friday, May 8
⏰08:50 - 09:10 am CEST (2:50 - 3:10 AM EST)
📍Munich Hall
We are seeking participants for the #ATTITUDEstudy, a research study focused on understanding attitudes toward #EndocrineTherapy for #BreastCancer.
👉This study aims to validate a new measure of patients’ attitudes toward endocrine therapy and better understand their experiences with long-term treatment.
👉The goal is to help identify patients who may struggle with #HormoneTherapyadherence and improve support strategies that help patients stay on treatment and reduce the risk of recurrence.
For more information email: [email protected]
PI: @MeganTesch #ClinicalTrial #BreastCancerResearch
Featured: Axillary Management and Outcomes After Neoadjuvant #EndocrineTherapy in the Randomized PELOPS Trial @AnnaWeissMD @TariKingMD
https://t.co/8LLkQRXwV1
@ChandlerCortina
@SyedAAhmad5
@SocSurgOnc
Learn how #EarlyMenopause from #EndocrineTherapy can impact young #BreastCancer survivors—and what steps can help protect your long‑term health. Read more: https://t.co/xtEsgemvlw
New treatments are helping #YoungSurvivors with hormone receptor–positive #BreastCancer live longer. However, #EndocrineTherapy can trigger #EarlyMenopause and understanding what to expect is key to protecting quality of life. https://t.co/uXhkXArykX
Thank you to @utswnews for highlighting our work on the role of the tumor immune microenvironment in resistance to #EndocrineTherapy in early-stage HR+ breast cancer, recently published @jclinicalinvest. @md_napolitano @CarlosArteagaMD @utswcancer https://t.co/8XrWCwpqg4
Thank you to @jclinicalinvest for highlighting our work, led by @md_napolitano! It's TIME to start paying attention to the tumor immune microenvironment and its role in #EndocrineTherapy resistance HR+ #breastcancer @utswcancer
🧵https://t.co/dX9RB99pip
It’s about TIME (tumor immune microenvironment) for #BreastCancer
Here, @md_napolitano, @AriellaHanker, and @CarlosArteagaMD and team @utswcancer analyze patient biopsies, finding CD8+ T cells in the TIME promote resistance to estrogen suppression in HR+ breast cancer via CXCL11 and immune-related pathways: https://t.co/8MlqbNvYkA
The images: GeoMx-based immunofluorescence of breast tumor tissue obtained during estrogen deprivation therapy (letrozole) demonstrates increased immune cell infiltration in estrogen deprivation–resistant tumors (right) compared with sensitive tumors (left).
HERA exploratory analysis: OFS is linked to lower recurrence in premenopausal HR+/HER2+ early breast cancer—despite chemo + trastuzumab.
Endocrine therapy is not redundant.
#BreastCancer #HER2 #Oncology #EndocrineTherapy #ASCO #ESMO @Medscape @OncoAlert @OncBrothers @dr_yakupergun @DanaFarber
• AIs = cut the fuel (estrogen)
• ESR1 mutations = engine runs without fuel
• SERDs = destroy the engine
• That’s why SERDs work when AIs don’t
#Oncology #BreastCancer #EndocrineTherapy #ESR1 #SERD
🙌Hot off the press @jclinicalinvest: #DoubleDoc and superstar @MDNapolitano delves into the role of the tumor immune microenvironment (TIME) in intrinsic resistance to #EndocrineTherapy in early-stage HR+ breast cancer. 🧵
@CarlosArteaga @UTSWcancer
https://t.co/qQbLCZkZwK
Giredestrant Outperforms Standard-of-Care Endocrine Therapy in Breast Cancer
Giredestrant significantly reduced the risk of recurrence compared to standard endocrine therapies in early-stage HR+ HER2- #breastcancer
@dradityabardia
#endocrinetherapy
https://t.co/f9m5Xm6e4z
Very interesting data presented in the rapid fire session at #SABCS25: smart pill bottles may improve adherence to #EndocrineTherapy in patients with #BreastCancer
@SABCSSanAntonio @OncoAlert #bcsm
#ESMO25: The combination giredestrant+everolimus showed a 44% reduction in risk of progression compared to #endocrinetherapy+everolimus in pts with ER-positive, HER2-negative advanced #BreastCancer previously treated w/ CDK4/6-inhibitors.
#ESMODailyReporter ➡️https://t.co/XNfCxwHek3
Check out:
🔎Assessing the Influence of #ProtonPumpInhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic #BreastCancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort
https://t.co/Jx2d0vnvdK
#endocrinetherapy #bioavailability
Joined @DrHBurstein contest during #ESMO25 @myESMO review: proposed algorithm for first- and second-line #EndocrineTherapy in ER-positive/HER2-negative metastatic #BreastCancer @OncoAlert
Preoperative Endocrine Therapy as an Approach to Assess Endocrine Sensitivity in ER+/HER2− Breast Cancer - Aleix Prat
@benjiwal
https://t.co/KSzNYrgnpT
#Cancer #Medicine #Health #Oncology #OncoDaily #BreastCancer #BCSM #EndocrineTherapy #MedX #MedNews #MedEd
New #esmo2025 data from #POSITIVE trial (#ABCSG 48): no increased #BreastCancer recurrence risk after temporary #endocrinetherapy interruption for pregnancy.
In collaboration with @BIGxResearch @etop_ibcsg 🔬
Last Seen Hashtags on Sotwe
legendahotwife
Seen from Brazil
AIErotic
Seen from Spain
teenage #nolimit() +filter:native_video
Seen from Turkey
سًَكًسٍَِ_محارًم
fartanimation
Seen from Korea
novinhos
Seen from Portugal
سِِكُسْ_كتَاب
Seen from Saudi Arabia
tıkaç
Seen from Turkey
ShoutMGB
Seen from United States
zeekbroexercises
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.4M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.1M followers
Taylor Swift
@taylorswift13
80.9M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
69M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.6M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.2M followers